Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.570 Biomarker group BEFREE Drugs targeting CB1R, CB2R, TRPV1 and PPARs are proven effective in animal models mimicking cardiovascular disorders such as hypertension, atherosclerosis and myocardial infarction. 29222605 2018
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.570 GeneticVariation group BEFREE The results obtained in the codominant and overdominant models for the <i>PPAR-y</i> polymorphism showed a tendency to statistical significance (the C/G genotype inclined to hypertriglyceridemia), and were statistically significant in the codominant, dominant, and recessive models (the C/C genotype predisposed to increased blood pressure). 29315078 2018
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.570 Biomarker group BEFREE The biological actions of PPARα and PPARγ and their potential as a cardiovascular therapeutic target have been extensively reviewed, whereas the biological actions of PPARβ/δ and its effectiveness as a therapeutic target in the treatment of hypertension remain less investigated. 27881385 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.570 Biomarker group BEFREE Importantly, TAFIa inhibitor and peroxisome proliferator-activated receptor-α agonists significantly reduced TAFIa and ameliorated animal models of pulmonary hypertension in mice and rats. 28289017 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.570 Biomarker group CTD_human These data suggest that increased PPARalpha expression is a protective mechanism in hypertensive renal injury induced by nitric oxide withdrawal/high salt diet and that siRNAs targeting the DNA-binding domain of PPARalpha gene elicited differential effects on hypertension and kidney injury. 19834340 2009
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.570 Therapeutic group CTD_human These data suggest that increased PPARalpha expression is a protective mechanism in hypertensive renal injury induced by nitric oxide withdrawal/high salt diet and that siRNAs targeting the DNA-binding domain of PPARalpha gene elicited differential effects on hypertension and kidney injury. 19834340 2009
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.570 Biomarker group RGD Skeletal muscle characteristics of rats with obesity, diabetes, hypertension, and hyperlipidemia. 19763017 2009
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.570 GeneticVariation group BEFREE Making the THM animals deficient in Peroxisome proliferator-activated receptor-alpha (THM/PPARKO) totally abolished hypertension and myocardial hypertrophy. 17909121 2007
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.570 Therapeutic group CTD_human Thus, apart from inhibition of ET-1 production, PPARalpha activation exerts protective actions in hypertension via a mechanism that involves NO production and/or inhibition of NAD(P)H oxidase activity. 16054168 2005
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.570 Therapeutic group RGD Therefore, chronic PPAR-alpha agonist treatment reduces salt-dependent hypertension produced by ETB receptor blockade in male and female Sprague-Dawley rats. 15967866 2005
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.570 Biomarker group CTD_human Thus, apart from inhibition of ET-1 production, PPARalpha activation exerts protective actions in hypertension via a mechanism that involves NO production and/or inhibition of NAD(P)H oxidase activity. 16054168 2005
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.570 GeneticVariation group BEFREE Hypertension linked to the PPAR-gamma2 Pro allele carriers was characterized by high leptin output during OLTT. 15202783 2004
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.570 GeneticVariation group BEFREE We demonstrate that variation in the PPARalpha gene influences human left ventricular growth in response to exercise and hypertension, indicating that maladaptive cardiac substrate utilization can play a causative role in the pathogenesis of LVH. 11864924 2002
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.570 GeneticVariation group LHGDN We demonstrate that variation in the PPARalpha gene influences human left ventricular growth in response to exercise and hypertension, indicating that maladaptive cardiac substrate utilization can play a causative role in the pathogenesis of LVH. 11864924 2002